September 20, 2017

September 19, 2017

Subscribe to Latest Legal News and Analysis

September 18, 2017

Subscribe to Latest Legal News and Analysis

Sales of Opioid Pain Medication Halted After FDA Request

Endo Pharmaceutical’s recent decision to halt sales of Opana ER (oxymorphone hydrochloride) quickly followed the U.S. Food and Drug Administration’s (FDA) request that it remove the abuse-linked opioid pain medication from the market. This is the first time the agency sought to remove a currently marketed opioid pain medication from sale due to the public health crisis of opioid abuse.

In 2015, more than 33,000 people died from opioid overdoses, according to the Centers for Disease Control. Almost half of the deaths involved a prescription medication.

The decision to request the withdrawal of Opana ER from the market arose from the FDA’s determination that the product had “dangerous unintended consequences” and abuse of reformulated Opana ER by injection resulted in a “serious disease outbreak.” The FDA’s decision was based on a review of post-marketing data, which demonstrated a pattern of abuse of Opana ER following the product’s reformulation in 2012. Injection abuse of reformulated Opana ER has been associated with a serious outbreak of HIV and hepatitis C, as well as cases of thrombotic microangiopathy, a serious blood disorder.

Opana ER was first approved in 2006. In 2012, Endo released the new formulation which was intended to make the drug resistant to abuse. At that time, the FDA declined the company’s request to include labeling describing Opana ER’s potentially abuse-deterrent properties. The FDA determined that the data did not show that the reformulation could be expected to meaningfully reduce abuse. Although Opana ER had been reformulated to discourage abuse by crushing or snorting – users began to liquefy and inject the drug.

Had Endo Pharmaceuticals chosen not to remove the product from the market, the FDA planned to require its removal by withdrawing approval. Meanwhile, the FDA informed health care professionals and others of the particularly serious risks associated with the abuse of Opana ER.

A number of lawsuits have been filed, mostly by states and municipalities, alleging that drugmakers downplayed the addictive risks of their opioid painkillers, while certain parts of the country were being devastated by opioid addiction.

Last year, the CDC released new voluntary guidelines for prescribing opioids, asking health care providers to consider alternatives to prescription painkillers, limit the length of treatment, and monitor patients.

COPYRIGHT © 2017, STARK & STARK

TRENDING LEGAL ANALYSIS


About this Author

Jeff Krawitz, Casualty Litigator, Stark and Stark Law firm
Shareholder

Jeff Krawitz is a Shareholder and member of Stark & Stark’s Accident & Personal Injury Group and concentrates his practice in casualty litigation focusing on complex injury, coverage issues and bad faith claims. He also has, and continues to, litigate claims arising from motor vehicle and transportation accidents, many of which involve catastrophic damages. His practice also includes the representation of litigants in professional liability claims including those involving medical negligence. Mr. Krawitz has extensive experience in both state and federal courts...

267-907-9606